BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

Alphamab Oncology Secures IND Acceptance In China For JSKN033 Phase II Cervical Cancer Study

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcu...

December 30, 2025 | News

Sobi Secures Positive CHMP Opinion For Aspaveli In Rare Kidney Diseases

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-...

December 30, 2025 | News

Japan Approves Sephience For All Ages Marking First PTC Product Clearance In The Country

– Indication includes all ages and the full spectrum of disease severity –– First Japan product approval for PTC – PTC T...

December 30, 2025 | News

Niowave Extends Actinium 225 Supply Agreement With AstraZeneca To Support Next Generation Cancer Therapies

Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca 10-year supply agreement ...

December 29, 2025 | News

HKSH Medical Group And Shenzhen Cancer Hospital Formalise Proton Therapy Collaboration Under Healthy China 2030 Framework

In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH")...

December 25, 2025 | News

NeuroSense Reports Clean Safety Profile From Phase 2 PrimeC Study In Alzheimer’s Disease

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for&nbs...

December 24, 2025 | News

Ginkgo Bioworks Joins Carnegie Mellon Led ARPA H Programme To Advance At Home Cancer Detection

Ginkgo Bioworks announced its partnership with Carnegie-Mellon University (CMU) for an award by the Advanced Research Projects Agency for Health...

December 24, 2025 | News

Japan Approves Guardant360 CDx As First Blood Based Companion Diagnostic For ESR1 Mutations In Breast Cancer

Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-posit...

December 23, 2025 | News

Japan Approves Incyte’s Zynyz As First Line Treatment For Advanced Anal Canal Cancer

Incyte Biosciences Japan G.K. announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination w...

December 23, 2025 | News

Merck Secures World First Regulatory Approval For Pimicotinib In Rare Joint Tumour TGCT In China

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantl...

December 23, 2025 | News

Meiji Seika Pharma Partners With MBC BioLabs To Strengthen Global Biotech Innovation

-Meiji Seika Pharma Co., Ltd. announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting ...

December 22, 2025 | News

Ferronova Raises $6 Million To Advance Nanoparticle Guided Cancer Surgery Technology

Australian company Ferronova has raised a further $6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solut...

December 18, 2025 | News

Atom Therapeutics Secures FDA Approval To Advance Phase II Trial Of ABP 745 In Atherosclerosis

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA ...

December 18, 2025 | News

Sanofi And Dren Bio Expand Strategic Collaboration To Advance Next Generation B Cell Depleting Therapies In Autoimmune Disease

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engag...

December 17, 2025 | News

Stay Connected